Literature DB >> 9312157

Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells.

L Sun1, C Chen.   

Abstract

Transforming growth factor beta (TGF-beta) promotes tumor progression in some model systems including human breast cancer cells. In this study, we report that human breast cancer cell lines express reduced amounts of TGF-beta type III receptor (RIII) when compared with untransformed human mammary epithelial cells. Consequently, we examined whether expression of RIII in human breast cancer MDA-MB-231 cells could reduce TGF-beta's tumor promoting activity by sequestering active TGF-beta isoforms produced by the cells. A tetracycline-repressible human RIII expression vector was stably transfected into the cell line. RIII expression in a pool of transfected clones and a single clone was found to be reversibly repressed by tetracycline treatment. Expression of RIII reduced the amount of active TGF-beta1 and TGF-beta2 in the conditioned medium. The medium conditioned by control cells showed a significantly higher growth inhibitory effect than that conditioned by RIII-transfected cells on the growth of the mink lung epithelial CCL64 cells. A conditioned medium collected from RIII-transfected cells treated with tetracycline significantly increased its growth inhibitory activity to that of control cells. Expression of RIII also reduced tumor incidence and growth rate in two separate experiments when the cells were inoculated in athymic nude mice. Treatment of the mice with tetracycline repressed RIII expression in the tumors generated by RIII-transfected cells and increased tumor incidence and growth rate. These results suggest that TGF-beta RIII can reduce tumorigenicity of MDA-MB-231 cells apparently by sequestering TGF-beta isoforms produced by these cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9312157     DOI: 10.1074/jbc.272.40.25367

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

2.  Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.

Authors:  M M Vilchis-Landeros; J L Montiel; V Mendoza; G Mendoza-Hernández; F López-Casillas
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

Review 3.  The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells.

Authors:  Molly A Taylor; Jenny G Parvani; William P Schiemann
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-15       Impact factor: 2.673

Review 4.  Roles for the type III TGF-beta receptor in human cancer.

Authors:  Catherine E Gatza; Sun Young Oh; Gerard C Blobe
Journal:  Cell Signal       Date:  2010-02-12       Impact factor: 4.315

5.  Elevated expression of CXC chemokines in pediatric osteosarcoma patients.

Authors:  Yiting Li; Ricardo Flores; Alexander Yu; M Fatih Okcu; Jeffrey Murray; Murali Chintagumpala; John Hicks; Ching C Lau; Tsz-Kwong Man
Journal:  Cancer       Date:  2010-08-30       Impact factor: 6.860

6.  Disruption of TGFbeta signaling pathways in human pancreatic cancer cells.

Authors:  D M Simeone; T Pham; C D Logsdon
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

7.  The type III TGF-beta receptor suppresses breast cancer progression.

Authors:  Mei Dong; Tam How; Kellye C Kirkbride; Kelly J Gordon; Jason D Lee; Nadine Hempel; Patrick Kelly; Benjamin J Moeller; Jeffrey R Marks; Gerard C Blobe
Journal:  J Clin Invest       Date:  2006-12-07       Impact factor: 14.808

8.  Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.

Authors:  Abhik Bandyopadhyay; Long Wang; Joseph Agyin; Yuping Tang; Shu Lin; I-Tien Yeh; Keya De; Lu-Zhe Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

9.  Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Authors:  Kaye L Stenvers; Melinda L Tursky; Kenneth W Harder; Nicole Kountouri; Supavadee Amatayakul-Chantler; Dianne Grail; Clayton Small; Robert A Weinberg; Andrew M Sizeland; Hong-Jian Zhu
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

10.  Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.

Authors:  Valentín Mendoza; M Magdalena Vilchis-Landeros; Guillermo Mendoza-Hernández; Tao Huang; Maria M Villarreal; Andrew P Hinck; Fernando López-Casillas; Jose-Luis Montiel
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.